Skip to content
Baret News – Lifestyle
Author:
Zymeworks Inc.
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
November 10, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
October 24, 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
October 23, 2026
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
October 19, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
October 15, 2026
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
September 28, 2026
Zymeworks Completes Acquisition of Theravance Biopharma
September 23, 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
August 25, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
August 11, 2026
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
1
2
Next Page
→